Wall Street Journal (06/24/97) P. B13
ICN Pharmaceuticals reports that it will acquire worldwide
rights to seven products currently owned by Roche Holding as
well as a Roche manufacturing facility in Puerto Rico and non-
U.S. rights to two other products. Under the terms of the
transaction, Roche will receive $15 million in cash and a 10
percent equity stake in ICN, valued at nearly $90 million.
ICN said it expects the seven products, which are used to
treat disorders of the central nervous system and skin cancer,
to boost its North American sales by about $52 million.
Proceeds will be used by the company to further develop
certain pharmaceuticals of its own, including Virazole, a new
therapy for hepatitis C. Related Stories: Financial Times
(06/24) P. 23; Investor's Business Daily (04/24) P. A2